(PRWEB) June 21, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a man who developed bladder cancer after taking Actos. Naming Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Co. as defendants, the suit was filed on June 14th in the U.S. District Court for the Western District of Louisiana (Case No. 6:12-cv-1696), where it is one of the many cases pending in the multidistrict litigation as part of In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Jerrold S. Parker, co-founder of Parker Waichman, has been appointed to the Plaintiffs’ Steering Committee. lawd.uscourts.gov/MDL2299;lawd.uscourts.gov/MDL2299/html/news.html
According to the complaint, the Plaintiff developed bladder cancer In July 2009, after taking Actos from 2007 to 2011. The lawsuit alleges that Actos caused the bladder cancer and other subsequent adverse events due to long-term use of the drug. The suit claims severe mental and physical pain and suffering, past and future permanent injuries and emotional distress, economic loss due to medical expenses and living related expenses as a result of a new lifestyle.
The suit further alleges that the Plaintiff would not have suffered these effects if the Defendants had not concealed the risks of the defective drug. In particular, the complaint points out the significant increased risk of bladder cancer associated with one year’s exposure, a link that was addressed by the U.S. Food and Drug Administration (FDA) last June in a Safety Announcement. Based on a data from an ongoing 10-year study by Kaiser Permanente, the agency stated that the risk of bladder cancer increased 40 percent after using Actos for one year in comparison to those who have never used the medication. This information was an update of the agency’s previous Safety Announcement in October 2010, which stated that the risk reached significance after two years. The FDA ordered a label change to address this risk. Health Canada, Canada’s healthcare regulatory agency, made similar adjustments to the Actos label in April. fda.gov/Drugs/DrugSafety/ucm226214.htm;fda.gov/Drugs/DrugSafety/ucm259150.htm; hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2012/actos_3_pc-cp-eng.php
Days before the FDA made its announcement last June, France and Germany suspended use of the drug; data indicated an increased risk of bladder cancer in male patients after one year of exposure.
Most recently, the British Medical Journal published a study finding a two-fold increased risk of bladder cancer in patients who had been exposed to the drug for more than two years. http://www.bmj.com/content/344/bmj.e3500?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bmj%2Frheumatology+%28Latest+Rheumatology+articles+from+the+BMJ%29
Parker Waichman LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm's Actos injury page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding Actos side effect lawsuits and Parker Waichman LLP, please visit http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney